Zobrazeno 1 - 10
of 498
pro vyhledávání: '"Kazuki YAMADA"'
Autor:
Stinchcombe, Norman
Publikováno v:
Musical Opinion Quarterly. Oct-Dec2024, Issue 1541, p71-72. 2p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kazuki Yamada, Takashi Inoue, Shuntaro Nakamura, Kazuhiro Horiuchi, Yutaka Tsutsumi, Satoru Munakata, Satoru Yagi, Yuki Fukami, Masahisa Katsuno, Ichiro Yabe
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Chronic lymphoproliferative disorder of natural killer cells (CLPD-NK) is a rare disease characterized by a persistent increase in NK cells in peripheral blood and is generally asymptomatic. If present, symptoms may include fatigu
Externí odkaz:
https://doaj.org/article/70e8ccaadbe34cb8ab70fe0bfa12213d
Autor:
Kazuhiro Horiuchi, Akihiko Kudo, Shuntaro Nakamura, Kazuki Yamada, Takashi Inoue, Shintaro Fujii, Yuki Oshima
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-6 (2024)
Abstract Background Dravet syndrome is a severe epilepsy disorder characterized by drug-resistant seizures and cognitive dysfunction, often caused by SCN1A gene mutations. It leads to neurodevelopmental delays and motor, behavioral, and cognitive imp
Externí odkaz:
https://doaj.org/article/2651727ee47d48e39acc97833b5bd630
Publikováno v:
Radiology Case Reports, Vol 17, Iss 7, Pp 2583-2588 (2022)
A 72-year-old female diagnosed with rectal cancer treated with a surgical procedure was reported. As 3 liver metastases (LMs) appeared in multidetector CT, adjuvant chemotherapy using Bevacizumab combined with modified FOLFOX-6 was completed. LMs wer
Externí odkaz:
https://doaj.org/article/c55432e307db43cab77a936b0b644a7a
Autor:
Stinchcombe, Norman
Publikováno v:
Musical Opinion Quarterly. Jul-Sep2023, Issue 1536, p57-57. 1/2p.
Autor:
Morley, Christopher
Publikováno v:
Musical Opinion Quarterly. Oct-Dec2021, Issue 1529, p44-45. 2p.
Autor:
Yasutaka Kakinoki, Kazuki Yamada, Yoko Tanino, Keiko Suzuki, Takaya Ichikawa, Naoki Suzuki, Go Asari, Ai Nakamura, Shin Kukita, Akito Uehara, Seisuke Saito, Shohei Kuroda, Hidemitsu Sakagami, Yuuki Nagashima, Kae Takahashi, Satoshi Suzuki
Publikováno v:
International Journal of Infectious Diseases, Vol 117, Iss , Pp 189-194 (2022)
ABSTRACT: Background: Recent data from clinical trials suggest that antibody cocktail therapy, which combined casirivimab and imdevimab, is linked to the reduction of the risk of hospitalization or death among high-risk patients with COVID-19. Howeve
Externí odkaz:
https://doaj.org/article/ecb306fb9eca44d887f35cf0a52e4838